Mineralys Therapeutics

Mineralys Therapeutics is a Radnor, Pennsylvania-based clinical-stage biopharmaceutical company founded in 2020 and focused on improving outcomes for patients managing hypertension, chronic kidney disease, and related conditions driven by dysregulated aldosterone. The company was founded by Catalys Pacific and in June 2026 priced a $150 million public offering.